Your browser doesn't support javascript.
loading
Decalogue for the selection of oral antibiotics for lower respiratory tract infections.
Cantón, R; Barberán, J; Linares, M; Molero, J M; Rodríguez-González-Moro, J M; Salavert, M; González Del Castillo, J.
Afiliación
  • Cantón R; Rafael Cantón. Servicio de Microbiología. Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS). Madrid. Spain. rafael.canton@salud.madrid.org.
  • González Del Castillo J; Juan Gonzalez del Castillo. Servicio de Urgencias, Hospital Clínico San Carlos and Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain. jgonzalezcast@gmail.com.
Rev Esp Quimioter ; 35(1): 16-29, 2022 Feb.
Article en En | MEDLINE | ID: mdl-35041328
ABSTRACT
Lower respiratory tract infections, including chronic obstructive pulmonary disease exacerbations (COPD-E) and community acquired pneumonia (CAP), are one of the most frequent reasons for consultation in primary care and hospital emergency departments, and are the cause of a high prescription of antimicrobial agents. The selection of the most appropriate oral antibiotic treatment is based on different aspects and includes to first consider a bacterial aetiology and not a viral infection, to know the bacterial pathogen that most frequently cause these infections and the frequency of their local antimicrobial resistance. Treatment should also be prescribed quickly and antibiotics should be selected among those with a quicker mode of action, achieving the greatest effect in the shortest time and with the fewest adverse effects (toxicity, interactions, resistance and/or ecological impact). Whenever possible, antimicrobials should be rotated and diversified and switched to the oral route as soon as possible. With these premises, the oral treatment guidelines for mild or moderate COPD-E and CAP in Spain include as first options beta-lactam antibiotics (amoxicillin and amoxicillin-clavulanate and cefditoren), in certain situations associated with a macrolide, and relegating fluoroquinolones as an alternative, except in cases where the presence of Pseudomonas aeruginosa is suspected.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones del Sistema Respiratorio / Infecciones Comunitarias Adquiridas Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Rev Esp Quimioter Asunto de la revista: TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones del Sistema Respiratorio / Infecciones Comunitarias Adquiridas Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Rev Esp Quimioter Asunto de la revista: TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article